Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep 28;107(10):2822-2832.
doi: 10.1210/clinem/dgac429.

Associations of Serum Vitamin B6 Status and Catabolism With All-Cause Mortality in Patients With T2DM

Dandan Zhang  1   2 , Yilan Li  1   2 , Xueyan Lang  1   2 , Yao Zhang  1   2
Affiliations

Associations of Serum Vitamin B6 Status and Catabolism With All-Cause Mortality in Patients With T2DM

Dandan Zhang et al. J Clin Endocrinol Metab. .

Erratum in

Abstract

Context: There is little evidence regarding the association between serum vitamin B6 status and catabolism and all-cause mortality in patients with type-2 diabetes mellitus (T2DM).

Objective: We aimed to ascertain if the serum level of vitamin B6 and catabolism, including pyridoxal 5'-phosphate (PLP) and 4-pyridoxic acid (4-PA), were associated with risk of all-cause mortality in T2DM patients.

Methods: This prospective cohort study involved 2574 patients with T2DM who participated in the National Health and Nutrition Examination Survey (NHANES) from 2005 to 2010. The serum concentrations of PLP and 4-PA were used to assess the serum level of vitamin B6. Mortality status was determined by routine follow-up using the National Death Index through December 31, 2015.

Results: Over a median follow-up of 85 months, there were 588 deaths. The fully adjusted Cox model indicated that the highest serum PLP concentrations (> 63.6 nmol/L) were associated with a decrease in all-cause mortality (hazard ratio [HR], 0.74; 95% CI, 0.55-0.99, P trend = .035). The risk for all-cause mortality was 59% higher for participants with the highest quartile of 4-PA level compared with the lowest quartile (HR, 1.62; 95% CI, 1.12-2.35; P trend = .003). The sensitivity and specificity of the combination of PLP and 4-PA levels for the prediction of all-cause mortality were 59.5% and 60.9%, respectively (area under the receiver operating characteristic curve = 0.632). The Kaplan-Meier method was used to estimate overall survival for patients based on different combinations of PLP level and 4-PA level. Patients with PLP less than 24.3 nmol/L and 4-PA greater than or equal to 25.4 nmol/L had the worst outcomes (log-rank P < .001).

Conclusion: Overall, our data suggest that a low serum level of PLP and high serum level of 4-PA, which represent the serum level of vitamin B6, increases the risk of all-cause mortality significantly in patients with T2DM.

Keywords: 4-pyridoxic acid (4-PA); NHANES; all-cause mortality; pyridoxal 5′-phosphate (PLP); serum vitamin B6; type 2 diabetes mellitus.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Flowchart of the screening process for the selection of eligible participants.
Figure 2.
Figure 2.
Association of A, pyridoxal 5′-phosphate (PLP) and B, 4-pyridoxic acid (4-PA) with all-cause mortality in unadjusted restricted cubic splines in National Health and Nutrition Examination Survey participants from 2005 to 2010.
Figure 3.
Figure 3.
Receiver operating characteristic curve analyses were used to evaluate the utility of A, pyridoxal 5′-phosphate (PLP), B, 4-pyridoxic acid (4-PA), and C, PLP combination with 4-PA in the prediction of all-cause mortality.
Figure 4.
Figure 4.
Kaplan-Meier plots of overall survival for patients based on different combinations of pyridoxal 5′-phosphate (PLP) status and 4-pyridoxic acid (4-PA) status. Log-rank P values are shown.
See this image and copyright information in PMC

References

    1. Saeedi P, Petersohn I, Salpea P, et al. IDF Diabetes Atlas Committee. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019;157:107843. doi: 10.1016/j.diabres.2019.107843 - DOI - PubMed
    1. Seshasai SRK, Kaptoge S, Thompson A, et al. Emerging Risk Factors Collaboration. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364(9):829-841. doi: 10.1056/NEJMoa1008862 - DOI - PMC - PubMed
    1. Stover PJ, Field MS. Vitamin B-6. Adv Nutr. 2015;6(1):132-133. doi: 10.3945/an.113.005207 - DOI - PMC - PubMed
    1. Mascolo E, Verni F. Vitamin B6 and diabetes: relationship and molecular mechanisms. Int J Mol Sci . 2020;21(10):18. doi: 10.3390/ijms21103669 - DOI - PMC - PubMed
    1. Lotto V, Choi SW, Friso S. Vitamin B-6: a challenging link between nutrition and inflammation in CVD. Br J Nutr. 2011;106(2):183-195. doi: 10.1017/s0007114511000407 - DOI - PubMed

Publication types